Search Results for: viral vector
News and Trends 29 Jun 2017
Servier Recruits Viral Vector Expert to Step Up its CAR-T Technology
Transgene will help Servier develop new methods based on viral vectors to improve the precision of genetic modifications and the production of CAR-T cells. The French pharma Servier decided to enter the promising CAR-T field in 2015, when it acquired the rights to UCART19 from Cellectis. The therapy, currently in Phase I, has already saved two babies […]
Interview 11 May 2017
Video: Meet the CEO developing Gene Therapy without Viral Vectors
Eyevensys has found a way to deliver gene therapy without viral vectors. Clara caught up with the company’s CEO Raffy Kazandjian at BioTrinity to hear more. Eyevensys is based in Paris and has set itself the mission of enhancing current treatment options in the field of ophthalmology. The biotech has developed a new gene therapeutic approach that […]
News and Trends 16 Dec 2016
This Gene Therapy Startup is Showing Off with a Better Viral Vector
GeneQuine wants to be one of the first to use gene therapy to treat osteoarthritis! Watch Kilian Guse’s pitch at Labiotech Refresh to find out how his startup plans to do this. “Osteoarthritis is the most common joint disorder. (…) Currently, there are only symptomatic treatments but no disease-modifying treatment“. One of the major challenges is efficient drug […]
News and Trends 3 Nov 2016
CEVEC is Revolutionizing Industrial Protein & Viral Vector Production
CEVEC just filed a Biologics Master File (BB-MF) to the FDA for its CAP technology, which outperforms all current standards in the production of gene therapy vectors and glycosylated human proteins. CEVEC is a Biotech with the mission of raising the industrial standard for the large-scale production of glycosylated proteins, viral vaccines and gene therapy […]
News and Trends 7 Jun 2016
German Biotech partners up in the US for scalable viral vector production in Gene Therapy
Cevec is joining forces with US-based Paragon. The objective is to make Cevec’s scalable CAP expression technology the industry standard for glycoproteins and viral vectors in gene therapies. Based in Cologne (Germany), Cevec tackles with its human cell-based expression systems (CAP-GT and CAP-Go) two big challenges in Biotech manufacturing – industrial scale production of viral vectors […]
News and Trends 12 May 2016
German Biotech achieves next step for Gene Therapy production of Viral Vectors
Cologne based Cevec specialises in producing tailor-made recombinant glycoproteins and gene therapy vectors. Now it has announced a breakthrough in their adenoviral vectors used in Gene Therapy. The increasing number of gene therapy-based discovery programs in the biotech and pharma industry is driving a greater need for the scalable production of gene therapy vectors. Vectors are needed […]
News and Trends 18 Jun 2015
German Viral Vector Producer SIRION pursues its American dream and opens in Boston
The biggest biocluster of the World is still attractive. Munich-based Sirion Biotech decided to open an office to establish its US presence and benefit from Boston’s leading position in the gene therapy field. Gene Therapy is the next big thing in Biotech and is now moving from a theoretical dream to reality. Boston is clearly the hotspot for […]
News and Trends 22 Feb 2015
Theravectys: an Orphan Drug Designation for Its Lentiviral Vector-Based Therapeutic Vaccine
THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapy, announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its therapeutic vaccine candidate for the treatment of Adult T-cell Leukemia/Lymphoma (ATL/L). ATL/L is a rare malignancy of a certain type of white cells, T-Lymphocytes, caused by the Human T-Cell Lymphotropic Virus type […]
News and Trends 16 Jun 2023
Key regulator of COVID viral receptor may be new drug target
Entry of the SARS-CoV-2 virus into human tissues depends on the activity of a host gene that regulates production of a key viral receptor, according to a study published in the open access journal PLOS Biology by Madison Strine and Craig Wilen of Yale University, U.S., and colleagues. The finding provides important new information on […]
News and Trends 10 May 2023
Delivering on the need for vector innovation in genetic medicine
By Tuyen Ong, CEO Ring Therapeutics, CEO-Partner Flagship Pioneering Gene therapy is a life-changing class of medicine that can treat patients with once intractable diseases. While revolutionary, significant limitations remain for the vectors that carry them. Viruses are masters at delivering genetic material to the nucleus of the organisms they infect, and because of this, […]
News and Trends 20 Sep 2022
GenScript and Avectas look to improve non-viral cell therapy manufacturing
GenScript USA Inc. and Avectas, a cell engineering technology company, are partnering to develop an improved non-viral cell therapy manufacturing process. The two companies said they share a goal of providing their customers with new methods for developing cell therapies with an improved safety profile over viral and non-viral vector techniques. By combining Avectas’ cell […]